AUTHORS
Nikhil Vojjala, MD, Raj Shah, MD2, Vijendra Singh, MD3
AFFILIATIONS
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 Kansas University Medical Center, Kansas City, Kansas, United States
3 Karmanos Cancer Institute, Detroit, Michigan, United States
ABSTRACT
Background
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder caused by factor VIII inhibitors and is associated with substantial morbidity and mortality. Contemporary real-world data describing treatment patterns and thrombotic complications remain limited. We evaluated contemporary treatment patterns, thrombotic events, and clinical factors associated with thrombosis in patients with AHA using the TriNetX Global Research Network.
Methods
We performed a retrospective observational cohort study using the TriNetX Global Research Network. Adult patients ≥18 years diagnosed with acquired hemophilia A were identified using standardized diagnostic codes. Baseline demographics, cardiovascular comorbidities, autoimmune diseases, malignancies, medication exposure, and treatment patterns were analyzed using descriptive statistics. The primary outcomes were thromboembolic events and all-cause mortality. Separate Cox proportional hazards analyses were performed to evaluate the association between selected baseline covariates and development of thrombotic events.
Results
A total of 809 patients with acquired hemophilia A were identified within the network. The mean age was 70.2 years, with 52.3% females. The cohort was predominantly white (65.3%), followed by Black/African American (16.2%). Cardiometabolic comorbidities were common, including hypertension (59%), hyperlipidemia (42%), type 2 diabetes mellitus (32%), chronic kidney disease (16%), cirrhosis (8%), and prior thromboembolic disease (12%). Solid organ malignancy constituted 25.9% (n=210), followed by 15.3% (n=124) autoimmune diseases and 8.7% (n=71) hematological malignancies. Prior COVID-19 infection or exposure was documented in 18% of patients. 26% were on antiplatelet therapy.
Regarding treatment patterns, 69% received corticosteroids, 12% cyclophosphamide, 6% emicizumab, and 4% intravenous immunoglobulin. Overall, 29.7% (n=241) received hemostatic therapies, including fresh frozen plasma, prothrombin complex concentrate, and/or recombinant activated factor VII (NovoSeven), while 9.7% (n=79) received NovoSeven alone.
The overall mortality was 8.2% (n=66). Thrombotic complications occurred in 17.2% (n=139), including acute myocardial infarction in 7.9% (n=64) and venous thromboembolism in 8.6% (n=69). In separate Cox proportional hazards analyses, obesity (HR 1.72, 95% CI 1.20–2.40), receipt of hemostatic therapies (HR 1.96, 95% CI 1.54–2.97), and underlying solid organ malignancy (HR 1.68, 95% CI 1.11–2.58) were each associated with an increased hazard of thrombotic events, whereas autoimmune diseases and hematologic malignancies were not significantly associated with thrombosis. Patients who developed thrombotic events had significantly higher mortality than those without thrombosis (15.1% vs 8.2%; HR 2.01, 95% CI 1.18–3.40).
Conclusions
In this large multicenter real-world analysis, patients with AHA experienced substantial thrombotic risk and associated mortality. Obesity, solid organ malignancy, and receipt of hemostatic therapies predicted the development of these thrombotic events. These findings highlight the need for careful patient selection, vigilant monitoring for thrombotic complications, and prospective studies to better define the optimal use of hemostatic therapies in AHA.
DISCLOSURES
Nikhil Vojjala, MD: No relevant conflicts of interest to declare.